ivermectin - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.16 [0.09, 15.55]< 10%2 studies (2/-)45.5 %some concernnot evaluable moderatecrucial-
deaths 0.63 [0.30, 1.29]< 10%7 studies (7/-)89.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.46 [0.27, 0.77]< 10%3 studies (3/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement 1.33 [0.77, 2.28]> 169%2 studies (2/-)84.8 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.28 [0.61, 2.70]> 191%2 studies (2/-)74.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.33 [0.77, 2.28]> 169%2 studies (2/-)84.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %some concernnot evaluable moderateimportant-
hospital discharge 1.14 [0.71, 1.84]> 10%2 studies (2/-)70.9 %some concernnot evaluable moderateimportant-
hospitalization 0.65 [0.32, 1.32]< 10%1 study (1/-)88.4 %lownot evaluable highimportant-
mechanical ventilation 1.25 [0.37, 4.20]< 10%3 studies (3/-)36.0 %some concernnot evaluable moderateimportant-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
viral clearance by day 14 0.76 [0.45, 1.28]> 10%1 study (1/-)15.0 %lownot evaluable highimportant-
viral clearance by day 7 1.09 [0.66, 1.80]> 162%3 studies (3/-)62.5 %some concernnot evaluable moderateimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (1/-)57.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.38 [0.31, 6.17]< 10%3 studies (3/-)33.8 %some concernnot evaluable moderateimportant-
adverse events 1.97 [0.55, 7.04]< 136%3 studies (3/-)15.0 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.66 [0.33, 1.30]< 10%1 study (1/-)88.4 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.